Monoclonal antibody strategies to block angiogenesis

This publication has 57 references indexed in Scilit:

• ‘Accidental’ anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
  European Journal Of Cancer, 2000
• Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells
  Oncogene, 2000
• Extensive Vasculogenesis, Angiogenesis, and Organogenesis Precede Lethality in Mice Lacking All αv Integrins
  Cell, 1998
• An Anti-Human VEGF Monoclonal Antibody, MV833, That Exhibits Potent Anti-Tumor ActivityIn Vivo
  Hybridoma, 1998
• In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11
  Anti-Cancer Drugs, 1997
• Role of Endogenous Basic Fibroblast Growth Factor in the Healing of Gastric Ulcers in Rats.
  The Japanese Journal of Pharmacology, 1997
• Requirement of Vascular Integrin α _v β ₃ for Angiogenesis
  Science, 1994
• Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
  Nature, 1993
• Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivo
  Biochemical and Biophysical Research Communications, 1989
• Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody
  New England Journal of Medicine, 1982